Financials data is unavailable for this security.
View more
Year on year Endonovo Therapeutics Inc had net income fall 495.02% from a loss of 3.10m to a larger loss of 18.47m despite a 85.15% increase in revenues from 73.11k to 135.36k.
Gross margin | 96.21% |
---|---|
Net profit margin | -1,722.26% |
Operating margin | -962.14% |
Return on assets | -388.54% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2022, cash reserves at Endonovo Therapeutics Inc fell by 85.84k. Cash Flow from Financing totalled 593.00k or 438.09% of revenues. In addition the company used 678.84k for operations while cash used for investing totalled .
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.072 |
---|---|
Tangible book value per share | -0.0745 |
More ▼
Balance sheet in USDView more
Current ratio | 0.0015 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼